Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

NCT05270733 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Ustekinumab

Sponsor

University Hospitals Cleveland Medical Center

Collaborators

[object Object]
[object Object]